17.12.2020 22:45:31
|
EU Agency Moves Forward Meeting On Moderna's COVID-19 Vaccine Approval
(RTTNews) - European Medicines Agency, the European Union's medicine regulator, said on Thursday that it has moved forward the date for a decision on authorizing Moderna's coronavirus vaccine to January 6 from January 12.
European Medicines Agency said Moderna, ahead of schedule, has submitted the last outstanding data package needed for the assessment of the application to approve mRNA-1273 COVID-19 vaccine
"Taking due account of the progress made, the Committee has scheduled an extraordinary meeting on 6 January 2021 to conclude its assessment, if possible. The meeting planned for 12 January 2021 will be maintained if needed," the regulator said in a statement.
"We have been able to revise the timetables for the evaluation of the COVID-19 vaccines due to the incredible efforts of everybody involved in these assessments: the chairs of the scientific committees, the rapporteurs and their assessment teams, scientific experts in all EU Member States and my staff at EMA," said Emer Cooke, EMA Executive Director.
Meanwhile, the U.S. FDA advisory committee are meeting on Thursday to decide whether to recommend the approval of Moderna's Covid-19 vaccine. The meeting comes after the Pfizer and BioNTech vaccine received an emergency use authorization.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Moderna Incmehr Nachrichten
03.02.25 |
Verluste in New York: S&P 500 verbucht zum Handelsende Verluste (finanzen.at) | |
03.02.25 |
Handel in New York: S&P 500 legt den Rückwärtsgang ein (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 präsentiert sich mittags schwächer (finanzen.at) | |
30.01.25 |
S&P 500-Papier Moderna-Aktie: So viel hätten Anleger mit einem Investment in Moderna von vor 5 Jahren verdient (finanzen.at) | |
30.01.25 |
Erste Schätzungen: Moderna stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
29.01.25 |
Minuszeichen in New York: S&P 500 beendet die Mittwochssitzung im Minus (finanzen.at) | |
29.01.25 |
Minuszeichen in New York: S&P 500 in der Verlustzone (finanzen.at) | |
29.01.25 |
Minuszeichen in New York: S&P 500 zum Start des Mittwochshandels schwächer (finanzen.at) |
Analysen zu Moderna Incmehr Analysen
19.11.24 | Moderna Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
13.09.24 | Moderna Underweight | JP Morgan Chase & Co. | |
05.08.24 | Moderna Sector Perform | RBC Capital Markets | |
12.01.24 | Moderna Outperform | RBC Capital Markets | |
03.11.23 | Moderna Buy | Goldman Sachs Group Inc. |
Aktien in diesem Artikel
Moderna Inc | 30,22 | 1,05% |
|